Growing Prevalence of Irritable Bowel Syndrome is expected to Drive Growth of the Global Irritable Bowel Syndrome Treatment Market
Irritable Bowel Syndrome Treatment Market
Irritable bowel syndrome is a
digestive system illness that causes stomach pain and changes in bowel habits.
It impairs the normal motility of intestinal muscular linings in the digestive
tract. The syndrome is classified as mild or severe irritable bowel syndrome
based on the severity of the symptoms. Cramping, abdominal pain, bloating and
gas, mucus in the stool, constipation, and diarrhoea are among the symptoms.
The rising prevalence of
irritable bowel syndrome (IBS) is likely to fuel Irritable
Bowel Syndrome Treatment Market expansion
over the forecast period. For example, according to an article published in
January 2021 by Cureus, an open access general medical journal, a cross-section
study was conducted in the internal medicine unit of a tertiary care hospital
in multiple cities of Pakistan from June 2019 to August 2019, to determine the
prevalence of IBS in a healthy population and the characteristics of symptoms.
According to the findings, the prevalence of IBS in the general population was
33.2%.
Increasing R&D initiatives by
key market players for the development of irritable bowel syndrome medications
are projected to fuel market expansion over the forecast period. For example,
on June 9, 2022, Ferring B.V. announced a strategic collaboration with I-MAB
Biopharma Co., Ltd., an innovation-driven global biopharma company, to further
develop olamkicept, a selective interleukin-6 (IL-6) trans-signaling inhibitor
for inflammatory bowel disease (IBD) and related inflammatory conditions.
Comments
Post a Comment